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INTRODUCTION
The introduction of renin-angiotensin-aldosterone
antagonists, beta-blockers and cardiac resynchroniza-
tion therapy has improved the prognosis of heart failure
(HF). The improvement in the treatment of HF has been,
however, attended by an increase of the importance of
comorbidities as major determinants of prognosis of
this syndrome. Among them, anemia is surely one of the
most important.
EPIDEMIOLOGY AND DEFINITIONS
The prevalence of anemia in patients with HF ranges
from 7%-10% to 70%-80% depending on differences in
HF severity, demographic variables and comorbidities
of the patients studied (1-3).
Definitions
There is not an universally recognized definition of
anemia. The World Health Organization (WHO) defines
anemia as a decrease in hemoglobin(Hb) values below
13 gm/dl in men and 12 gm/dl in women (2). The Na-
tional Kidney Foundation defines anemia as Hb values
<13.5 gm/dl in adult men and <12 gm/dl in adult women
(values based on the average of the lower quintile of the
standard population ) (4).
In a retrospective analysis of the Studies of Left Ven-
tricular Dysfunction (SOLVD), Al-Ahmad et al have
shown that  the prevalence of anemia could change
from 22% to 4% according to differences in the hemat-
ocrit threshold value (<0.39%, corresponding to serum
hemoglobin of 13 gm/dl and <0.35%, corresponding
to12 gm/dl, respectively) (5).
Predisposing factors
The prevalence of anemia increases with HF severity
(5). Other parameters related to HF severity, such as left
ventricular (LV) ejection fraction, blood pressure, BNP
or NT-proBNP plasma concentrations, are associated to
the prevalence of anemia (1-3, 6, 7, 10). Left ventricular
ejection fraction (LVEF) has an inverse relationship with
serum Hb levels and this relation is maintained also
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when patients with preserved left ventricular systolic
function are included (7).
The prevalence of anemia also depends on the pa-
tients’ demographic characteristics, since it is more fre-
quent in the elderly, female and black patients (8, 9). Co-
morbidities, namely renal failure and diabetes, are fre-
quently and independently related to anemia (1-3, 6, 7,
10).
Recent onset anemia
New onset anemia frequently develops during the
clinical course of HF. The Carvedilol or Metoprolol Euro-
pean Trial (COMET) enrolled 3029 patients who were
followed for 58 months. In this trial the incidence of re-
cent onset anemia was of 14% at 1 year and 27.5% at 5
years. At multivariate analysis the predictive factors of
recent onset anemia were age, high furosemide dose,
increase of serum creatinine, hyponatremia, hyper-
kaliemia, and lack of aldosterone-antagonist adminis-
tration (6). Another study had shown different predictive
factors: low serum albumin, glomerular filtration rate,
body weight, diastolic arterial pressure, an increase in
furosemide dose, C-reactive protein, BNP levels and
LVEF. These studies also showed that carvedilol (6) and
valsartan (10) therapy, respectively, can be independent
predictors of new onset anemia.
MECHANISMS
The pathogenesis of anemia in patients with HF is
multifactorial (Tab. I).
Hemodilution
Anemia is correlated to HF severity. Patients with HF
often show signs of congestion. Water retention and in-
crease in plasma volume can cause a “pseudo-anemia”
due to hemodilution (11). Ritz et al showed that in 97 pa-
tients with HF the reduction of glomerular filtration, ery-
thropoietin levels and expanded plasma volume were
independent predictive factors of low Hb levels. Some
studies, conducted using the radiolabeled albumin
technique, have demonstrated that up to 46% of pa-
tients with HF and anemia have hemodilution along with
a normal red blood cells number (12). Although a lower
incidence of hemodilution has been reported in other
studies, this mechanism should be excluded in anemic
patients with HF (13). In these patients treatment should
be diuretic therapy, while erythropoietin administration
could further increase total blood volume with possible
adverse clinical consequences (2).
There is a relevant percentage of anemic patients
with HF but without hemodilution. In these patients, the
cause is likely iron deficiency, chronic kidney disease,
cachexia and angiotensin converting enzyme (ACE) in-
hibitors therapy.
Iron deficiency
The prevalence of iron deficiency in patients with HF
is variable from 30% to 73% (13).
The higher percentage has been found in a study in
which iron deficiency was measured also in the bone
marrow. The inflammatory response in patients with HF
leads to the reduction of iron absorption and anticoagu-
lant and/or antiaggregant therapy could cause gastroin-
testinal bleeding. On the other hand, the iron resources
in anemic patients with HF could be normal or high be-
cause of increased iron uptake and storage in
macrophages (reticuloendothelial system) with a conse-
quent reduction of its availability for hematopoiesis (14,
15). Intravenous iron therapy has been shown to in-
crease serum Hb levels (from 11.2+0.7 to 12.6+1.2 g/dl,
p=0.0007) as well as to improve exercise tolerance,
quality of life and functional class (16). B12 and folate
deficiency has not a significant role in pathogenesis of
anemia in patients with HF (17).
TABLE I - MAIN FACTORS RELATED TO ANEMIA IN PATIENTS
WITH HEART FAILURE
Demographic factors (age, gender, race)
Water and salt retention
Iron deficiency
Renal failure
Chronic inflammatory activation 
Concomitant treatment
- Angiotensin Converting Enzyme Inhibitors
- Angiotensin receptor blockers
- Non selective beta-blockers (carvedilol)Metra et al
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Renal failure 
Moderate to severe chronic renal failure (glomerular
filtration rate <60 ml/min) is one of the main determi-
nants of anemia (1, 2, 5, 17, 18). In 30%-40% of patients
with HF an inverse correlation between serum creatinine
and plasmatic Hb has been reported. Chronic kidney
disease causes anemia through a reduction in erythro-
poietin production, although patients with HF can show
increased levels of erythropoietin (18-20). The main
cause of anemia in HF, similarly to other chronic dis-
eases associated to inflammatory processes, is resis-
tance to erythropoietin effects rather than its reduced
production (14).
Cytokines
Reduced body mass and cardiac cachexia have been
shown to be important predictive factors for anemia in
patients with HF (2, 6, 7). The activation of pro-inflam-
matory cytokines (TNF-α, interleukine-6, interleukine-
10, interferon-γ, lipopolysaccharides) is important for
both anemia and cardiac cachexia pathogenesis. Pro-
inflammatory cytokines could have many effects: stimu-
lation of erythropoietin, inhibition of gut iron absorption,
inhibition of the proliferation of progenitor red cells, in-
creased apoptosis, red cells damage, increased ery-
throphagocitosis, increased uptakes and storage of iron
into macrophages, resistance to erythropoietin. All these
effects may ultimately lead to reduced erythropoiesis (Fig.
1, Tab. II) (21). Chronic inflammation causes reduced iron
availability, that is stored by macrophages of the reticulo-
endothelial system (22, 23).
Concomitant therapy
Neuro-hormonal antagonist and, namely, ACE-in-
hibitors and angiotensin II receptors blockers  are im-
portant causes of anemia in patients with HF. An analy-
sis of the SOLVD study has shown that enalapril is an in-
dependent predictive factor for low Hb levels (23). The
Valsartan Heart Failure (VAlHeFT) trial has confirmed
these data for angiotensin II receptors blockers (10).
Angiotensin II increases erythropoietin secretion
through hypoperfusion and renal hypoxia and, thus, can
directly stimulate erythropoiesis (24). Antagonists of
renin-angiotensin system, blocking the effects of an-
giotensin II, also reduce erythropoiesis. Moreover, ACE
catalyzes the demolition of N-Acetil-seril-lisil-proline
(Ac-SKPD), a tetra peptide inhibitor of the proliferation
of haematopoietic stem cells. ACE inhibitor administra-
tion causes an increase in the plasmatic concentrations
of this substance with a consequent development of
anemia (25).
Fig. 1 - Pathogenetic mechanism
of anemia in patients with heart
failure.
Continuous lines show favourable
effects. Outlines show inhibition
mechanisms. The renal failure de-
termines a reduced erythropoietin
production. Citokines increase
erythropoietin production but in-
hibit erythropoiesis with erythro-
poietin resistance, reduced iron
availability and half life of red
cells. Angiotensin converting en-
zyme inhibitors reduce renal pro-
duction of erythropoietin by di-
rect effects and increasing renal
perfusion.
Erythropoietin
production
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Differences between beta-blockers may also be im-
portant.  An analysis of the Carvedilol or Metoprolol Eu-
ropean Trial (COMET) has shown that carvedilol therapy
is associated with a slight but significant Hb decrease
(0.2 g/dl) compared to metoprolol therapy (6). Renal
cells secreting  erythropoietin or progenitor red cells
have sympathetic  innervation with beta-1, beta-2, and
alpha adrenergic receptors (26). Beta-2 receptors have
the most important role and carvedilol could cause a
decrease in Hb levels through its non selective action on
beta-2 andrenergic receptors.   
ANEMIA AND CLINICAL OUTCOMES
Many retrospective analyses of clinical trials have
shown that reduced Hb levels are independently associ-
ated with an increased risk of hospitalisation and mor-
tality in patients with HF (1-3, 5-10, 12, 27-30). A recent
re-analysis of SOLVD trial shows that anemia is also an
independent risk factor related to new onset kidney dis-
ease (31). Some studies have demonstrated that anamia
was an independent predictor for HF mortality but not for
sudden cardiac death (6, 9). Anemia is associated with
poor outcome not only in patients with  LV systolic dys-
function, but also in patients with asymptomatic LV dys-
function (5, 32) or with preserved LVEF (7, 30).
There is a linear relationship between reduced Hb
serum levels and increased mortality risk: a 1-mg/dl de-
crease Hb levels has been associated to an increase in
mortality of 13% (relative risk [RR], 1.13; 95% confi-
dence interval [95% IC], 1.045-1.224) (2). Low Hb levels
are related to severe prognosis but it is yet unclear the
effect of an increased Hb serum level. There is usually a
linear relationship between high Hb levels and reduced
mortality and morbidity risk. However,  Sharma et al in
the “Evaluation of Losartan in the Elderly II” (ELITE II) tri-
al showed a U-shaped relation between Hb concentra-
tion and mortality risk. A minimum mortality risk was
shown for physiological serum values (13 e 15 g/dl)
while a major mortality rate was demonstrated for
serum values >15 g/dl (28). Go et al in 59772 patients
with HF (3) showed an increased mortality risk with Hb
levels >17 g/dl (Fig. 2). However, other comorbidities
(such as chronic obstructive pulmonary disease, COPD)
could have influenced the outcome, especially in the el-
derly patients. 
Changes in Hb levels during the clinical course of HF
could influence the prognosis. Results from COMET trial
have shown that patients with a 2-3 g/dl decrease in
serum Hb have an increased mortality risk of 47% (RR,
1.466; 95%IC, 1.092-1.969; p=0.0109), while a Hb reduc-
tion >3 g/dl was associated to a three fold greater mortal-
ity rate (RR, 3.37; IC95%, 2.464-4.611; p<0.0001) (6).
TABLE II - EFFECTS OF CYTOKINES ON IRON METABOLISM AND ERYTHROPOIESIS 
Cause Mechanism Effects
↑TNF-α, IF-γ, IL-1  ↓proliferation and differentiation ↑ progenitors cells apoptosis;  erythropoietin resistance; 
toxic effects induced by free radicals;   ↓ erythropoiesis
↓ erythropoietin receptor expression 
↑TNF-α, IL-6, IF-γ,   ↑ferritin transcription  ↑ferritin  
LPS, IL-10
TNF-α, IL-6, IF-γ,   Red cells damage  (free radicals?) ↑red cells fagocitosis  ↓half life red cells
LPS, IL-10 by macrophages      ↑storage and iron retention 
in macrophage 
↓sideremy  
IL-6  ↑Epcidin: ↓iron enteric uptake  ↓sideremy  
IF-γ, LPS  ↑Divalent Metal transporter 1 (DIMT 1), ↓ferroportin  ↓sideremy, ↓ iron availability 
for progenitor cells  
TNF= Tumor Necrosis Factor; IF = interferon; IL = interleukin; LPS= lipopolysaccharides (2, 14).Metra et al
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Mechanisms (Tab. III)
Myocardial Hypertrophy. Anemia is strictly related to
cardiac hypertrophy (33, 34). These evidences have
been confirmed in an analysis of “The Randomized
Etanecerpt North American Strategy to Study Antago-
nism of Cytokines (RENAISSANCE) Trial” (31). In 66 pa-
tients the Hb values were related to the LV myocardial
mass assessed by magnetic resonance imaging (MRI)
after six-months follow-up. LV myocardial index (LVMI)
increased by +1.6+7.9 g/m2 in patients with stable o de-
creased Hb values while it decreased by -7.5+12.1 g/m2
in patients with increased serum Hb level (p=0.0008).
An inverse correlation was observed between changes
in Hb levels and LVMI changes (r=0.32, P=0.0086) (31).
However, other clinical trials did not find any relation-
ship between changes in serum Hb values and LV my-
ocardial mass and no favourable effect of increased Hb
levels on cardiac structure and function have been
shown, to date (35-39).
Oxygen uptake in peripheral tissues. The de-
creased availability of oxygen substrates to the pe-
ripheral tissues represents another untoward effect of
anemia. In patients with anemia and HF the reduced
cardiac output can not compensate the reduced Hb
levels and this could explain the more severe symp-
toms of anaemic patients, with a more severe impair-
ment in exercise capacity and a greater risk of rehos-
pitalisation (8). A positive correlation has been shown
between peak VO2 and serum Hb values (40, 41). The
administration of erythropoiesis stimulating agents
(ESA) has been related to an improvement in exercise
capacity either in patients with renal failure (42) or in
patients with HF (16, 43, 44).
The reduced peripheral oxygen demand can lead to
an increased cardiac work with a consequent myocar-
dial ischaemia and LV remodelling increasing mortality
and cardiovascular hospitalisation (2, 3).
Other Mechanisms. Anemia causes neurohormonal
activation, oxidative stress and reduced nitric oxide
production (30). It may also cause salt and water reten-
tion and peripheral edema with consequent poor prog-
nosis in patients with HF (2).
Anemia can also be considered a consequence of HF
severity. Its exact role in HF must, however, be shown
by controlled trials showing an improvement in survival
with anemia correction.
TREATMENT APPROACHES
Hemotransfusion. According to the American Guide-
lines, blood transfusion is recommended for Hb levels in
the range from 6 to 8 g/dl. The clinical utility of  hemo-
transfusion for higher Hb levels is still unsettled. Gener-
ally, hemotransfusion is not considered for Hb values
>10 g/dl (45).
In 78, 974 elderly patients hospitalised with acute
myocardial infarction, blood transfusion was associated
with a lower mortality rate at 30 days in patients with an
hematocrit < 30% on admission (46). Conversely,  in 838
patients (26% with cardiovascular disease), stable Hb
levels between 10-12 g/dl did not provide additional
Fig. 2 - J-shaped relation between the serum hemoglobin levels
and mortality risk in 59, 772 patients with heart failure (3).
TABLE III - NEGATIVE EFFECTS OF ANEMIA ON OUTCOME IN
PATIENTS WITH HEART FAILURE
Myocardial hypertrophy
Reduced oxygen uptake in peripheral tissues
- Increased cardiac output
Neuro-hormonal activation
Worsening renal failure
Edema and fluid retention inductionAnemia and heart failure: a cause of progression or only a consequence?
6
benefits on mortality compared with Hb concentration
of 7-9 g/dl (47).
Moreover, the blood transfusion may be associated
with some adverse effects such as immunosuppression,
increased infection risk, iron overload and the sensitiza-
tion to HLA antigens (48). Transfusion may be considered
only an acute phase treatment for severe anemia and it is
not available as a long-term therapeutic strategy. 
Iron therapy. It is commonly accepted that patients
with chronic HF have relative iron deficiency (2, 22). To-
tal body iron content may be normal. However, HF, like
other chronic inflammatory diseases, is associated to
increased uptake and storage of iron within the reticulo-
endothelial system (11, 14). Thus, less iron is available
for erythropoiesis despite possibly increased total body
iron stores (so called “reticulo-endothelialblock”).
Several small studies have demonstrated that iron
therapy may cause a slight but significant increase in
serum Hb levels and improve symptoms and exercise
tolerance (16, 49).The IRON-HF study is an ongoing tri-
al designed to assess the clinical impact of iron supple-
mentation (intravenous or oral administration), com-
pared to placebo, in patients with HF and low serum
iron and transferrin concentrations (50).
Iron therapy is also used in association with ESA. Cur-
rent guidelines from the National Kidney Foundation rec-
ommend the use of intravenous iron (because of the re-
duced enteric absorption) to maintain serum ferritin lev-
els of 100 to 800 ng/ml and a transferrin saturation of
20% to 50% in order to optimize the response to ESA (4).
It must be, however, pointed out that high doses iron
therapy has severe side effects such as an increased
oxydative stress with endothelial dysfunction and athero-
sclerosis progression (51).
Erythropoiesis stimulating agents (ESA)
An increased level of serum erythropoietin can occur
in patients with HF and is correlated to a more severe
outcome (18, 19). However, erythropoietin levels of HF
patients with anemia are lower, compared to patients
with similar Hb levels without HF. In addition, HF, like
other chronic inflammatory diseases, is associated to
peripheral resistance to erythropoietin actions (11, 22,
53). This is mainly caused by the neurohormonal and in-
flammatory activation. ACE inhibitor therapy may also
play a role (23, 24). These observations suggest an im-
portant role for therapy with ESA, associated with iron
supplementation, in patients with anemia and HF.
Available agents. There are three currently available
ESA for the treatment of anemia: epoetin-α, epoetin-β
(both of which are recombinant human erythropoietins,
rHuEpo) and darbepoetin-α (analog of human erythro-
poietin). These agents can be administered either intra-
venously or subcutaneously. Plasma half-life of epoetin-
α and epoetin-β after intravenous dosing is 6 to 8 hours.
After subcutaneous administration, the plasma half-life
is increased to more of 24 hours. Thus, epoetin-α and
epoetin-β should be administered subcutaneously once
to three times a week. Darbepoetin-α has a stronger
affinity for erythropoietin receptors with a longer plasma
half-life (approximately 48 hours), and, hence, longer
dosing intervals (1 to 2 weeks) may be used during
maintenance therapy (2, 4).
Clinical efficacy. The effect of rHuEpo treatment in
anaemic patients with HF was first reported by Silve-
berg et al in 2000 (52). Twenty-six anemic patients with
advanced HF and serum Hb <12 g/dl were treated with
subcutaneous rHuEpo and intravenous iron sucrose.
After 6-7 months of treatment with rHuEpo, mean Hb
levels increased from 10.2 g/dl to 12.1 g/dl, with an im-
provement in New York Heart Association (NYHA) func-
tional class, LVEF (from 28±5% to 35±8%, p<0.001),
decreased needs for intravenous furosemide and a de-
creased hospitalisation rate (54). The same investiga-
tors reported a significant reduction in hospitalisations
and days of hospitalisation in another randomised open
label trial in 32 patients (53).
Mancini et al conduced a single-blind, randomised,
placebo-controlled trial of rHuEpo therapy in 26 pa-
tients with advanced HF and anemia (hematocrit <35%)
(43). Patients received 5000 Units of subcutaneous
rHuEpo three times per week and supplemental oral iron
and folate, adjusted to raise hematocrit to >45%. Com-
pared with the placebo group, rHuEpo therapy was as-
sociated with significant increase in Hb values from
11.0±0.5 to 14.3±1.0 g/dl, with a concomitant increase
in treadmill exercise duration and peak oxygen uptake
(11.0±1.8 to 12.7±2.8 ml/min per kilogram, p<0.05). In-
creases in serum Hb levels were linearly related to peak
oxygen uptake changes. 
Another more recent study conducted in Italy con-
firmed the clinical benefits of rHuEpo therapy. Forty pa-
tients with severe HF were randomised to receive, in aMetra et al
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double blind fashion, either subcutaneous rHuEpo for
three months twice a week, or placebo (saline solution).
The treated group showed a significant increase in Hb
values (from 10.4±0.6 to 12.4±0.8 g/dl, p<0.01), an im-
provement in NYHA functional class (from 3.5±0.6 to
2.8±0.5, p<0.05), and an increase in peak oxygen con-
sumption (from 12.8±2.8 to 15.1±2.8 ml/Kg per minute,
p<0.05). There was also a fall in plasma BNP levels, a
reduction in serum creatinine and an increase in esti-
mated creatinine clearance (54).
Studies with Darbepoetin-α. In a randomized, place-
bo-controlled trial in 41 patients with HF and anemia,
darbepoetin-α administration, once every 2 weeks for
26 weeks, was associated with an increase in serum Hb
values from 11.8±0.2 to 13.9±0.4 g/dl (versus 11.6±0.2
to 12.3±0.4 g/dl in the placebo group). Darbepoetin-α
administration was also associated to an improvement
in quality of life, evaluated by the patients’ Global As-
sessment score. However, the Kansas City Cardiomy-
opathy and the Minnesota Living with Heart Failure
scores, exercise duration and peak VO2 did not show
any significant change compared to placebo. Peak VO2
increased by 0.5 ml/Kg/min in the darbepoetin-α group,
versus +0.1 ml/Kg/min in the placebo group (p=0.40).
No significant correlation between Hb concentrations
and exercise tolerance was shown (44).
Although the results of this trial may have been
caused by chance, they may also suggest that a more
rigorous approach, with double-blind placebo control,
allowed a more accurate assessment of the real effects
of therapy with ESA on quality of life and exercise toler-
ance, compared to previous studies (43). It might also
be that the number of patients studied was insufficient
to reach statistical significance. In the MIRACLE trial
(Multicenter InSync Randomized Clinical Evaluation)
enrolment of 369 patients was necessary to show a sig-
nificant improvement in exercise tolerance with CRT
versus control (55).
A recent combined analysis of two randomised dou-
ble-blind, placebo-controlled trials comparing darbepo-
etin-α versus placebo in 475 patients did not show any
improvement in NYHA class and Quality of Life with dar-
bepoetin-α. This study also showed a trend to a de-
crease in the risk of composite outcome (death or HF
hospitalization) and mortality in the darbepoetin-α
group versus placebo group (39/266, 15% vs 46/209,
22%; HR 0.67, 95% CI 0.44-1.03, p=0.06) with also a
tendency to a lower mortality in the darbepoetin-α
group (6% vs 9%; HR, 0.76) (49, 56).
A large-scale, mortality trial on 3400 patients with
anemia and HF (Reduction of Events with Darbepoetin-
α in Heart Failure, RED-HF) is ongoing and will likely de-
finitively show the effects of darbepoetin-α on outcome
in these patients (56).
Optimal target level of Hb. In November 2006, two
large-scale, controlled studies with ESA in patients with
chronic kidney disease (CKD) were published (Correc-
tion of Hemoglobinand Outcomes in Renal Insufficiency
[CHOIR] and Cardiovascular Risk reduction by Early
Anemia Treatment with Epoetin beta [CREATE]) (57, 58).
Both these studies were prematurely stopped because
of a tendency to a worse outcome in the ESA treated
patients (59, 60). In CHOIR, 1432 patients with anemia
and renal insufficiency (23% patients with a history of
HF), were treated with two different erythropoietin
regimes to reach Hb target levels of 13.5 g/dl or 11.3
g/dl. During a median follow-up of 16 months, the high-
er Hb target group had an increase in the composite
endpoint of death, myocardial infarction, HF hospitali-
sation and stroke (HR, 1.34; p=0.03). There was also a
tendency to an increased risk of the composite end
point of death or nonfatal myocardial infarction in the
group assigned to a higher hematocrit (HR, 1.3; 95% CI
0.9-1.9) (61).
Differently, in CREATE study (57) (603 patients with
anemia and renal failure, 33% with HF), there was not an
increase in cardiovascular events in the patients as-
signed to reach the target Hb levels after epoietin-β
treatment (13.0-15.0 gm/dl). However, the number of
patients requiring haemodialysis and with high blood
pressure values was greater in the group assigned to
higher target Hb values (13 vs 23). Similar results were
obtained  in another study in diabetic patients (38, 58).
A tendency to an increase in the risk of death was
shown by preliminary results of two studies in patients
with cancer and anemia. 
On the basis of these results, on 9 march 2007, the
Food and Drug  Administration (FDA) recommended to
avoid the achievement of Hb levels >12 g/dl and to stop
erythropoietin therapy when these are > 12 g/dl. The ad-
ministration of low doses of ESA are still recommended
with Hb values < 10 g/dl (60). The National Kidney Foun-
dation recommends to achieve a serum Hb value of 11-
12 g/dl (4, 60).Anemia and heart failure: a cause of progression or only a consequence?
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Adverse effects of ESA administration. The increased
cardiovascular events rates in patients with high level of
Hb after ESA therapy may be due to increased blood
viscosity and high blood pressure (59).
The increased blood viscosity associated with high
hematocrit in patients with diffuse atherosclerosis and
kidney disease, increases thrombotic events. Direct ef-
fect of erythropoietin on platelets and endothelium in-
creases the thrombotic risk (62). These evidences are
not confirmed in patients with HF because the frequent
concomitant therapy with antiplatelet and anticoagulant
medications may reduce prothrombotic effects of ery-
thropoietic agents. To confirm these data, large trials
with long-term follow up are necessary (49, 59).
ESA therapy causes an increased blood pressure by
increased blood viscosity, activation of the neurohor-
monal system, and direct effects on microvascular
structure and function. However, blood pressure was
significantly increased only in a single study (58) and in
patients with HF no changes in blood pressure or in pe-
ripheral resistances have been observed after erythro-
poietin therapy (60).
RECOMMENDATIONS AND FUTURE DIRECTIONS
The role of anemia as an independent prognostic fac-
tor is now well known. Anemia is frequent in patients
with advanced HF and its aetiology is generally multi-
factorial. It is not only related with impaired renal perfu-
sion and kidney failure, but also it could be triggered by
an inflammatory and neurohormonal activation and/or
by renin angiotensin system therapy. The prognostic
value of anemia is not clear and there are no evidences
about the correction of low Hb values and improving
survival rate in patients with HF.
The administation of erithropoietic stimulating agents
remains the more effective therapy to improve Hb serum
level. According to the 2005 Guidelines about the diag-
nosis and treatment of chronic HF of the European So-
ciety of Cardiology (ESC), anemia is a risk factor for
worsening Hf but the treatment is not defined (63). Ac-
cording to the 2005 Guidelines of American Heart Asso-
ciation (AHA)/American College of Cardiology (ACC),
benefits of ESA therapy in anaemic patients with HF has
not been shown, yet, (class IIB recommendation, level
of evidence C) (64).The treatment with ESA is common-
ly considered effective only in patients with kidney dis-
eases (4).
In HF patients with moderate-to-severe anemia (Hb
< 11 g/dl), current guidelines of FDA and of National
Kidney Foundation recommend treatment with ESA to
reach  Hb target value of 10-12 g/dl and improve the
quality of life. However, there are no clinical data sup-
porting the use of ESA to improve the outcome in HF
patients. Large trials with long term follow up are
needed to determine the effects on morbidity and
mortality (59).
ESA may have antiapoptotic and antischaemic ef-
fects with a pro-angiogenic activity on endothelial cells
(3, 65-68). Cytoprotective and antiapoptotic effects
have been shown (69, 70) as well as a beneficial action
on central nervous system injury and in experimental
models of myocardial hypoxia. These evidences
showed the possibility that derivatives of rHuEpo may
be useful to protect cardiomyocites by ischaemic injury
and to improve the myocardial function in patients with
HF, rather than reducing other co-morbidities.
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